2951
|
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10:871-5. [PMID: 15247913 PMCID: PMC7095806 DOI: 10.1038/nm1080] [Citation(s) in RCA: 554] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2003] [Accepted: 03/26/2004] [Indexed: 12/15/2022]
Abstract
Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10−8M to 10−11M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.
Collapse
Affiliation(s)
- Elisabetta Traggiai
- Institute for Research in Biomedicine, Via Vela 6, Belllinzona, CH 6500 Switzerland
| | - Stephan Becker
- Institut für Virologie, Robert-Koch-Str. 17, Marburg, D-35037 Germany
| | - Kanta Subbarao
- Laboratory of Infectious Diseases, NIAID/NIH, 50 South Drive, Bethesda, 20892-8007 Maryland USA
| | | | | | - Maria Rita Gismondo
- Istituto di Microbiologia, Ospedale Luigi Sacco, Via Grassi 74, Milano, I-20175 Italy
| | - Brian R Murphy
- Laboratory of Infectious Diseases, NIAID/NIH, 50 South Drive, Bethesda, 20892-8007 Maryland USA
| | - Rino Rappuoli
- Chiron Vaccines, Via Fiorentina 1, Siena, I-53100 Italy
| | - Antonio Lanzavecchia
- Institute for Research in Biomedicine, Via Vela 6, Belllinzona, CH 6500 Switzerland
| |
Collapse
|
2952
|
Wu Q, Xu Z, Wei T, Zeng H, Li J, Gang H, Sun M, Jiang F, Wang X, Dong W, Yang L, Wang J. Development of Taqman RT-nested PCR system for clinical SARS-CoV detection. J Virol Methods 2004; 119:17-23. [PMID: 15109816 PMCID: PMC7119531 DOI: 10.1016/j.jviromet.2004.02.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2003] [Revised: 01/29/2004] [Accepted: 02/12/2004] [Indexed: 11/26/2022]
Abstract
Severe acute respiratory syndrome (SARS) is an acute newly emerged infectious respiratory illness. The etiologic agent of SARS was named ‘SARS-associated coronavirus’ (SARS-CoV) that can be detected with reverse transcription-polymerase chain reaction (RT-PCR) assays. In this study, 12 sets of nested primers covering the SARS-CoV genome have been screened and showed sufficient sensitivity to detect SARS-CoV in RNA isolated from virus cultured in Vero 6 cells. To optimize further the reaction condition of those nested primers sets, seven sets of nested primers have been chosen to compare their reverse transcribed efficiency with specific and random primers, which is useful to combine RT with the first round of PCR into a one-step RT-PCR. Based on the sensitivity and simplicity of results, the no. 73 primer set was chosen as the candidate primer set for clinical diagnoses. To specify the amplicon to minimize false positive results, a Taqman RT-nested PCR system of no. 73 nested primer set was developed. Through investigations on a test panel of whole blood obtained from 30 SARS patients and 9 control persons, the specificity and sensitivity of the Taqman RT-nested PCR system was found to be 100 and 83%, respectively, which suggests that the method is a promising one to diagnose SARS in early stages.
Collapse
Affiliation(s)
- Qingfa Wu
- Beijing Genomics Institute, Chinese Academy of Sciences, Airport Industrial Zone, Bldg 6, Beijing 101300, PR China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2953
|
Qinfen Z, Jinming C, Xiaojun H, Huanying Z, Jicheng H, Ling F, Kunpeng L, Jingqiang Z. The life cycle of SARS coronavirus in Vero E6 cells. J Med Virol 2004; 73:332-7. [PMID: 15170625 PMCID: PMC7166737 DOI: 10.1002/jmv.20095] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2004] [Indexed: 12/16/2022]
Abstract
The aim of the study was to establish the life cycle of severe acute respiratory syndrome-associated coronavirus (SARS CoV) in host cells and determine the pathogenesis of SARS. Vero E6 cells (African green monkey kidney cells) were inoculated with SARS coronavirus for 3, 7, 24, 48, and 72 hr, respectively, and were observed under electron microscope. It was found that the SARS coronavirus entered the cells through membrane fusion instead of endocytosis, and then the nucleocapsids assembled in the RER and matured by budding into the smooth vesicles, which were derived from the Golgi apparatus. The smooth vesicles fused with the cell membrane, and the mature particles were released. A special phenomenon was that some virus-like particles appeared in the nucleus. We propose a scheme of the life cycle of SARS coronavirus and discuss the mechanism of its replication in Vero E6 cells.
Collapse
Affiliation(s)
- Zhang Qinfen
- State Key Lab for Biocontrol, Zhongshan University, Guangzhou, China
| | - Cui Jinming
- State Key Lab for Biocontrol, Zhongshan University, Guangzhou, China
| | - Huang Xiaojun
- State Key Lab for Biocontrol, Zhongshan University, Guangzhou, China
| | - Zheng Huanying
- Center for Disease Control and Prevention of Guangdong Province, Guangzhou, China
| | - Huang Jicheng
- Center for Disease Control and Prevention of Guangdong Province, Guangzhou, China
| | - Fang Ling
- Center for Disease Control and Prevention of Guangdong Province, Guangzhou, China
| | - Li Kunpeng
- State Key Lab for Biocontrol, Zhongshan University, Guangzhou, China
| | - Zhang Jingqiang
- State Key Lab for Biocontrol, Zhongshan University, Guangzhou, China
| |
Collapse
|
2954
|
Loon SC, Teoh SCB, Oon LLE, Se-Thoe SY, Ling AE, Leo YS, Leong HN. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004; 88:861-3. [PMID: 15205225 PMCID: PMC1772213 DOI: 10.1136/bjo.2003.035931] [Citation(s) in RCA: 205] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2003] [Indexed: 11/03/2022]
Abstract
BACKGROUND Severe acute respiratory syndrome (SARS) is a new infectious disease that caused a global outbreak in 2003. Research has shown that it is caused by a novel coronavirus. A series of cases is reported where polymerase chain reaction (PCR) testing on tears had demonstrated the presence of the virus. Detection of ocular infection from tears using the PCR technique has been widely used by ophthalmologists to diagnose infections for other viruses. METHODS This is a case series report from cases classified as probable or suspect SARS cases. Tear samples were collected from 36 consecutive patients who were suspected of having SARS in Singapore over a period of 12 days (7-18 April 2003), and analysed by PCR using protocols developed by the WHO network of laboratories. RESULTS Three patients with probable SARS (one female and two male patients) had positive results from their tear samples. Tear samples were used to confirm SARS in the female patient, who was positive only from her tears. The positive specimens were found in cases sampled early in their course of infection. CONCLUSIONS This is the first case series reported with the detection of the SARS coronavirus from tears, and has important implications for the practice of ophthalmology and medicine. The ability to detect and isolate the virus in the early phase of the disease may be an important diagnostic tool for future patients and tear sampling is both simple and easily repeatable. Many healthcare workers are in close proximity to the eyes of patients and this may be a source of spread among healthcare workers and inoculating patients. Ophthalmic practices may need to change as more stringent barrier methods, appropriate quarantine, and isolation measures are vital when managing patients with SARS.
Collapse
Affiliation(s)
- S-C Loon
- Eye Institute, Tan Tock Seng Hospital, Singapore, Republic of Singapore.
| | | | | | | | | | | | | |
Collapse
|
2955
|
Romero D, Gómez-Zapata M, Luna A, García-Fernández AJ. Comparison of cytopathological changes induced by mercury chloride exposure in renal cell lines (VERO and BGM). ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2004; 17:129-141. [PMID: 21782724 DOI: 10.1016/j.etap.2004.03.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2003] [Accepted: 03/31/2004] [Indexed: 05/31/2023]
Abstract
The response to mercury chloride was assessed in two cell lines of renal origin, determining the range of toxic concentrations by Neutral Red assay after 24-h of exposure. Morphological changes in the Buffalo Green Monkey (BGM) and VERO cell lines after exposure to subcytotoxic doses (0.045 and 0.038mM, respectively) equivalent to EC10 (effective concentrations 10%) of mercury chloride were evaluated at the structural and ultrastructural level by optic, transmission and scanning microscopy. Using transmission electron microscopy, the most notable findings in treated cells were the presence of intracytoplasmic inclusion bodies and apoptotic bodies. Scanning microscopy pointed to a cell with a disrupted perinuclear region and a decreased number of surface microvilli. Similar alterations in both in vivo and in vitro experiments have been described by other authors. We conclude that BGM and VERO renal cell lines can be considered as useful tools for toxicological studies involving mercury chloride.
Collapse
Affiliation(s)
- D Romero
- Department of Toxicology, School of Veterinary Medicine, University of Murcia, Espinardo Campus, E-30100 Murcia, Spain
| | | | | | | |
Collapse
|
2956
|
Agranovski IE, Safatov AS, Pyankov OV, Sergeev AN, Agafonov AP, Ignatiev GM, Ryabchikova EI, Borodulin AI, Sergeev AA, Doerr HW, Rabenau HF, Agranovski V. Monitoring of viable airborne SARS virus in ambient air. ATMOSPHERIC ENVIRONMENT (OXFORD, ENGLAND : 1994) 2004; 38:3879-3884. [PMID: 32288549 PMCID: PMC7129584 DOI: 10.1016/j.atmosenv.2004.03.044] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2003] [Revised: 02/23/2004] [Accepted: 03/10/2004] [Indexed: 05/20/2023]
Abstract
Due to recent SARS related issues (Science 300 (5624) 1394; Nature 423 (2003) 240; Science 300 (5627) 1966), the development of reliable airborne virus monitoring procedures has become galvanized by an exceptional sense of urgency and is presently in a high demand (In: Cox, C.S., Wathers, C.M. (Eds.), Bioaerosols Handbook, Lewis Publishers, Boca Raton, FL, 1995, pp. 247-267). Based on engineering control method (Aerosol Science and Technology 31 (1999) 249; 35 (2001) 852), which was previously applied to the removal of particles from gas carriers, a new personal bioaerosol sampler has been developed. Contaminated air is bubbled through porous medium submerged into liquid and subsequently split into multitude of very small bubbles. The particulates are scavenged by these bubbles, and, thus, effectively removed. The current study explores its feasibility for monitoring of viable airborne SARS virus. It was found that the natural decay of such virus in the collection fluid was around 0.75 and 1.76 lg during 2 and 4 h of continuous operation, respectively. Theoretical microbial recovery rates of higher than 55 and 19% were calculated for 1 and 2 h of operation, respectively. Thus, the new sampling method of direct non-violent collection of viable airborne SARS virus into the appropriate liquid environment was found suitable for monitoring of such stress sensitive virus.
Collapse
Affiliation(s)
- Igor E Agranovski
- Faculty of Environmental Sciences, Griffith University, Brisbane, 4111 QLD, Australia
| | - Alexander S Safatov
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Oleg V Pyankov
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander N Sergeev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander P Agafonov
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Georgy M Ignatiev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Elena I Ryabchikova
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander I Borodulin
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Artemii A Sergeev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Hans W Doerr
- Institute for Medical Virology, Johann Wolfgang Goethe University, D-60596 Frankfurt/Main, Germany
| | - Holger F Rabenau
- Institute for Medical Virology, Johann Wolfgang Goethe University, D-60596 Frankfurt/Main, Germany
| | - Victoria Agranovski
- School of Physical and Chemical Sciences, Queensland University of Technology, Brisbane, 4000 QLD, Australia
| |
Collapse
|
2957
|
Tan YJ, Teng E, Shen S, Tan THP, Goh PY, Fielding BC, Ooi EE, Tan HC, Lim SG, Hong W. A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis. J Virol 2004; 78:6723-34. [PMID: 15194747 PMCID: PMC421683 DOI: 10.1128/jvi.78.13.6723-6734.2004] [Citation(s) in RCA: 130] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2003] [Accepted: 02/23/2004] [Indexed: 01/28/2023] Open
Abstract
The severe acute respiratory syndrome coronavirus (SARS-CoV) genome contains open reading frames (ORFs) that encode for several genes that are homologous to proteins found in all known coronaviruses. These are the replicase gene 1a/1b and the four structural proteins, nucleocapsid (N), spike (S), membrane (M), and envelope (E), and these proteins are expected to be essential for the replication of the virus. In addition, this genome also contains nine other potential ORFs varying in length from 39 to 274 amino acids. The largest among these is the first ORF of the second longest subgenomic RNA, and this protein (termed U274 in the present study) consists of 274 amino acids and contains three putative transmembrane domains. Using antibody specific for the C terminus of U274, we show U274 to be expressed in SARS-CoV-infected Vero E6 cells and, in addition to the full-length protein, two other processed forms were also detected. By indirect immunofluorescence, U274 was localized to the perinuclear region, as well as to the plasma membrane, in both transfected and infected cells. Using an N terminus myc-tagged U274, the topology of U274 and its expression on the cell surface were confirmed. Deletion of a cytoplasmic domain of U274, which contains Yxxphi and diacidic motifs, abolished its transport to the cell surface. In addition, U274 expressed on the cell surface can internalize antibodies from the culture medium into the cells. Coimmunoprecipitation experiments also showed that U274 could interact specifically with the M, E, and S structural proteins, as well as with U122, another protein that is unique to SARS-CoV.
Collapse
Affiliation(s)
- Yee-Joo Tan
- Institute of Molecular and Cell Biology, 30 Medical Dr., Singapore 117609, Singapore.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2958
|
Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, Ng MHL, Chan P, Cheng G, Sung JJY. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8. [PMID: 15214887 PMCID: PMC7129386 DOI: 10.1111/j.1469-0691.2004.00956.x] [Citation(s) in RCA: 274] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Treatment of severe acute respiratory syndrome (SARS) is experimental, and the effectiveness of ribavirin-steroid therapy is unclear. Forty SARS patients with progressive disease after ribavirin treatment and 1.5 g of pulsed methylprednisolone were given either convalescent plasma (n = 19) or further pulsed methylprednisolone (n = 21) in a retrospective non-randomised study. Good clinical outcome was defined as discharge by day 22 following the onset of symptoms. Convalescent plasma was obtained from recovered patients after informed consent. Patients in the plasma group had a shorter hospital stay (p 0.001) and lower mortality (p 0.049) than the comparator group. No immediate adverse effects were observed following plasma infusion.
Collapse
Affiliation(s)
| | - Y. Cheng
- Departments of Medicine and Therapeutics
| | - R. Wong
- Departments of Medicine and Therapeutics
| | - D. S. Hui
- Departments of Medicine and Therapeutics
| | | | | | | | - P. Chan
- Microbiology, The Chinese University of Hong Kong, Hong Kong
| | - G. Cheng
- Departments of Medicine and Therapeutics
| | | |
Collapse
|
2959
|
Affiliation(s)
- James D Cherry
- David Geffen School of Medicine at UCLA and Mattel's Children's Hospital at UCLA, Department of Pediatrics, Los Angeles, CA 90095-1752, USA.
| | | |
Collapse
|
2960
|
Guery B, Georges H, Labalette M, Leroy O, d'Escrivan T, Gonin X, Mouton Y, Dessaint JP, Yazdanpanah Y. Acute respiratory distress syndrome and severe acute respiratory syndrome: circulating interleukin 4 level could be a marker. Med Mal Infect 2004; 34:328-30. [PMID: 15679239 PMCID: PMC7127567 DOI: 10.1016/j.medmal.2004.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- B Guery
- Reanimation Médicale et Maladies Infectieuse, Center Hospitalier de Tourcoing, Hopital Chatillez, CH Dron, 135, rue du Pdt Coty, 59208 Tourcoing, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
2961
|
Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M, Kuate S, Uberla K, Niedrig M, Pöhlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004; 78:6134-42. [PMID: 15163706 PMCID: PMC416513 DOI: 10.1128/jvi.78.12.6134-6142.2004] [Citation(s) in RCA: 161] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.
Collapse
Affiliation(s)
- Heike Hofmann
- Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg, Nikolaus-Fiebiger-Center, Glückstrasse 6, D-91054 Erlangen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2962
|
Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol 2004; 32:567-82. [PMID: 14676007 PMCID: PMC7154303 DOI: 10.1080/03079450310001621198] [Citation(s) in RCA: 225] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Vaccines against infectious bronchitis of chickens (Gallus gallus domesticus) have arguably been the most successful, and certainly the most widely used, of vaccines for diseases caused by coronaviruses, the others being against bovine, canine, feline and porcine coronaviruses. Infectious bronchitis virus (IBV), together with the genetically related coronaviruses of turkey (Meleagris gallopovo) and ring-necked pheasant (Phasianus colchicus), is a group 3 coronavirus, severe acute respiratory syndrome (SARS) coronavirus being tentatively in group 4, the other known mammalian coronaviruses being in groups 1 and 2. IBV replicates not only in respiratory tissues (including the nose, trachea, lungs and airsacs, causing respiratory disease), but also in the kidney (associated with minor or major nephritis), oviduct, and in many parts of the alimentary tract--the oesophagus, proventriculus, duodenum, jejunum, bursa of Fabricius, caecal tonsils (near the distal end of the tract), rectum and cloaca (the common opening for release of eggs and faeces), usually without clinical effects. The virus can persist, being re-excreted at the onset of egg laying (4 to 5 months of age), believed to be a consequence of the stress of coming into lay. Genetic lines of chickens differ in the extent to which IBV causes mortality in chicks, and in respect of clearance of the virus after the acute phase. Live attenuated (by passage in chicken embryonated eggs) IBV strains were introduced as vaccines in the 1950s, followed a couple of decades later by inactivated vaccines for boosting protection in egg-laying birds. Live vaccines are usually applied to meat-type chickens at 1 day of age. In experimental situations this can result in sterile immunity when challenged by virulent homologous virus. Although 100% of chickens may be protected (against clinical signs and loss of ciliary activity in trachea), sometimes 10% of vaccinated chicks do not respond with a protective immune response. Protection is short lived, the start of the decline being apparent 9 weeks after vaccination with vaccines based on highly attenuated strains. IBV exists as scores of serotypes (defined by the neutralization test), cross-protection often being poor. Consequently, chickens may be re-vaccinated, with the same or another serotype, two or three weeks later. Single applications of inactivated virus has generally led to protection of <50% of chickens. Two applications have led to 90 to 100% protection in some reports, but remaining below 50% in others. In practice in the field, inactivated vaccines are used in laying birds that have previously been primed with two or three live attenuated virus vaccinations. This increases protection of the laying birds against egg production losses and induces a sustained level of serum antibody, which is passed to progeny. The large spike glycoprotein (S) comprises a carboxy-terminal S2 subunit (approximately 625 amino acid residues), which anchors S in the virus envelope, and an amino-terminal S1 subunit (approximately 520 residues), believed to largely form the distal bulbous part of S. The S1 subunit (purified from IBV virus, expressed using baculovirus or expressed in birds from a fowlpoxvirus vector) induced virus neutralizing antibody. Although protective immune responses were induced, multiple inoculations were required and the percentage of protected chickens was too low (<50%) for commercial application. Remarkably, expression of S1 in birds using a non-pathogenic fowl adenovirus vector induced protection in 90% and 100% of chickens in two experiments. Differences of as little as 5% between the S1 sequences can result in poor cross-protection. Differences in S1 of 2 to 3% (10 to 15 amino acids) can change serotype, suggesting that a small number of epitopes are immunodominant with respect to neutralizing antibody. Initial studies of the role of the IBV nucleocapsid protein (N) in immunity suggested that immunization with bacterially expressed N, while not inducing protection directly, improved the induction of protection by a subsequent inoculation with inactivated IBV. In another study, two intramuscular immunizations of a plasmid expressing N induced protective immunity. The basis of immunity to IBV is not well understood. Serum antibody levels do not correlate with protection, although local antibody is believed to play a role. Adoptive transfer of IBV-infection-induced alphabeta T cells bearing CD8 antigen protected chicks from challenge infection. In conclusion, live attenuated IBV vaccines induce good, although short-lived, protection against homologous challenge, although a minority of individuals may respond poorly. Inactivated IBV vaccines are insufficiently efficacious when applied only once and in the absence of priming by live vaccine. Two applications of inactivated IBV are much more efficacious, although this is not a commercially viable proposition in the poultry industry. However, the cost and logistics of multiple application of a SARS inactivated vaccine would be more acceptable for the protection of human populations, especially if limited to targeted groups (e.g. health care workers and high-risk contacts). Application of a SARS vaccine is perhaps best limited to a minimal number of targeted individuals who can be monitored, as some vaccinated persons might, if infected by SARS coronavirus, become asymptomatic excretors of virus, thereby posing a risk to non-vaccinated people. Looking further into the future, the high efficacy of the fowl adenovirus vector expressing the IBV S1 subunit provides optimism for a live SARS vaccine, if that were deemed to be necessary, with the possibility of including the N protein gene.
Collapse
Affiliation(s)
- Dave Cavanagh
- Institute for Animal Health, Division of Molecular Biology, Compton Laboratory, Newbury, Berkshire, UK.
| |
Collapse
|
2963
|
Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363:2122-7. [PMID: 15220033 PMCID: PMC7112367 DOI: 10.1016/s0140-6736(04)16501-x] [Citation(s) in RCA: 213] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease. METHODS We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. FINDINGS Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. INTERPRETATION A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.
Collapse
Affiliation(s)
- Alexander Bukreyev
- Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
2964
|
Hertzig T, Scandella E, Schelle B, Ziebuhr J, Siddell SG, Ludewig B, Thiel V. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 2004; 85:1717-1725. [PMID: 15166457 DOI: 10.1099/vir.0.80044-0] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
A previously unknown coronavirus (CoV) is the aetiological agent causing severe acute respiratory syndrome (SARS), for which an effective antiviral treatment is urgently needed. To enable the rapid and biosafe identification of coronavirus replicase inhibitors, we have generated a non-cytopathic, selectable replicon RNA (based on human CoV 229E) that can be stably maintained in eukaryotic cells. Most importantly, the replicon RNA mediates reporter gene expression as a marker for coronavirus replication. We have used a replicon RNA-containing cell line to test the inhibitory effect of several compounds that are currently being assessed for SARS treatment. Amongst those, interferon-alpha displayed the strongest inhibitory activity. Our results demonstrate that coronavirus replicon cell lines provide a versatile and safe assay for the identification of coronavirus replicase inhibitors. Once this technology is adapted to SARS-CoV replicon RNAs, it will allow high throughput screening for SARS-CoV replicase inhibitors without the need to grow infectious SARS-CoV.
Collapse
Affiliation(s)
- Tobias Hertzig
- Institute of Virology and Immunology, University of Würzburg, Würzburg, Germany
| | - Elke Scandella
- Research Department, Cantonal Hospital St Gallen, CH-9007 St Gallen, Switzerland
| | - Barbara Schelle
- Institute of Virology and Immunology, University of Würzburg, Würzburg, Germany
| | - John Ziebuhr
- Institute of Virology and Immunology, University of Würzburg, Würzburg, Germany
| | - Stuart G Siddell
- Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, Bristol, UK
| | - Burkhard Ludewig
- Research Department, Cantonal Hospital St Gallen, CH-9007 St Gallen, Switzerland
| | - Volker Thiel
- Research Department, Cantonal Hospital St Gallen, CH-9007 St Gallen, Switzerland
| |
Collapse
|
2965
|
Abstract
PURPOSE OF REVIEW Severe acute respiratory syndrome (SARS) is a new disease that caused large outbreaks in several countries in the first half of 2003, resulting in infection in more than 8000 people and more than 900 deaths. During that time, a large body of literature rapidly emerged describing the clinical disease, the etiologic viral agent, and management options. This paper reviews the current status of this knowledge base, with particular reference to the critically ill patient. RECENT FINDINGS Case series of patients from Hong Kong, China, Singapore, and Toronto have characterized the disease with remarkable uniformity. A similarly consistent picture of the SARS patient with respiratory failure has emerged from studies from Toronto and Singapore. Worldwide collaboration led to the rapid identification and gene sequencing of the etiologic virus, SARS-CoV. SUMMARY SARS is a predominantly respiratory illness, spread through droplets from respiratory secretions and possibly via a fecal-oral route. A small number of "super-spreaders" appear to have contributed to the rapid proliferation of the disease. Infection control precautions are an essential component of management. Approximately 20% of patients develop progressive pulmonary infiltrates and respiratory failure, and the mortality rate is as high as 10%. Treatment strategies with antiviral agents such as ribavirin have not clearly demonstrated a benefit, but high-dose corticosteroids appear to be beneficial in patients with progressive disease. The recent outbreaks highlighted the potential for this disease to overwhelm critical care resources, by the volume of patients and loss of healthcare workers to illness and quarantine.
Collapse
Affiliation(s)
- Stephen E Lapinsky
- Mount Sinai Hospital, University Health Network, and the Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada.
| | | |
Collapse
|
2966
|
Yu CJ, Chen YC, Hsiao CH, Kuo TC, Chang SC, Lu CY, Wei WC, Lee CH, Huang LM, Chang MF, Ho HN, Lee FJS. Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus. FEBS Lett 2004; 565:111-6. [PMID: 15135062 PMCID: PMC7126674 DOI: 10.1016/j.febslet.2004.03.086] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2004] [Revised: 03/22/2004] [Accepted: 03/30/2004] [Indexed: 12/03/2022]
Abstract
The open reading frame 3 of the severe acute respiratory syndrome coronavirus (SARS‐CoV) genome encodes a predicted protein 3a, consisting of 274 amino acids, that lacks any significant similarities to any known protein. We generated specific antibodies against SARS protein 3a by using a synthetic peptide (P2) corresponding to amino acids 261–274 of the putative protein. Anti‐P2 antibodies and the sera from SARS patients could specifically detect the recombinant SARS protein 3a expressed in Escherichia coli and in Vero E6 cells. Expression of SARS protein 3a was detected at 8–12 h after infection and reached a higher level after ∼24 h in SARS‐CoV‐infected Vero E6 cells. Protein 3a was also detected in the alveolar lining pneumocytes and some intra‐alveolar cells of a SARS‐CoV‐infected patient's lung specimen. Recombinant protein 3a expressed in Vero E6 cells and protein 3a in the SARS‐CoV‐infected cells was distributed over the cytoplasm in a fine punctate pattern with partly concentrated staining in the Golgi apparatus. Our study demonstrates that SARS‐CoV indeed expresses a novel protein 3a, which is present only in SARS‐CoV and not in other known CoVs.
Collapse
Affiliation(s)
- Chia-Jung Yu
- Department of Medical Research, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan
| | - Yee-Chun Chen
- Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
| | - Cheng-Hsiang Hsiao
- Department of Pathology, National Taiwan University Hospital, Taipei 100, Taiwan
| | - Tse-Chun Kuo
- Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
- Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
| | - Shin C. Chang
- Institute of Microbiology, National Taiwan University, College of Medicine, Taipei 100, Taiwan
| | - Chun-Yi Lu
- Department of Pediatrics, National Taiwan University Hospital, Taipei 100, Taiwan
| | - Wen-Chin Wei
- Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Chia-Huei Lee
- Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Li-Min Huang
- Department of Pediatrics, National Taiwan University Hospital, Taipei 100, Taiwan
| | - Ming-Fu Chang
- Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Hong-Nerng Ho
- Department of Medical Research, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan
- Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei 100, Taiwan
| | - Fang-Jen S. Lee
- Department of Medical Research, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 100, Taiwan
- Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
| |
Collapse
|
2967
|
Zhang J, Meng B, Liao D, Zhou L, Zhang X, Chen L, Guo Z, Peng C, Zhu B, Lee PP, Xu X, Zhou T, Deng Z, Hu Y, Li K. De novo synthesis of PCR templates for the development of SARS diagnostic assay. Mol Biotechnol 2004; 25:107-12. [PMID: 14526121 PMCID: PMC7090507 DOI: 10.1385/mb:25:2:107] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A novel coronavirus was identified as the cause for severe acute respiratory syndrome (SARS). The complete sequence of SARS genome has provided an opportunity for the development of molecular diagnostic assays. To restrain further outbreak of SARS, the World Health Organization has posted several pairs of polymerase chain reaction (PCR) primers for early diagnosis and urged more research to be done on PCR protocols. Here we report a strategy for the de novo synthesis of PCR templates complimentary to the SARS virus genome, which has the advantage of working on PCR templates without concern about viral infection and also has the advantage that it can be used by those who do not have access to the SARS virus. This highly efficient and safe strategy for obtaining SARS gene fragments is useful for the development of PCR assays, as well as for the preparation of reliable positive controls for PCR testing kits.
Collapse
Affiliation(s)
| | - Bo Meng
- Shanghai Institute of Brain Functional Genomics, East China Normal University, Shanghai
| | - Duanfang Liao
- Institute of SNP, Institute of Pharmacy and Pharmacology, National University, Hengyang
| | - Lvyi Zhou
- Shanghai Institute of Brain Functional Genomics, East China Normal University, Shanghai
| | | | | | | | | | - Bingyang Zhu
- Institute of SNP, Institute of Pharmacy and Pharmacology, National University, Hengyang
| | - Peggy P. Lee
- University of California in San Diego, San Diego, USA
| | - Xiangmin Xu
- Department of Medical Genetics, The First Military Medical University, Guangzhou
| | - Tianhong Zhou
- Institute of Life Science and Biotechnology, Jinana University, Guangzhou
| | - Zemin Deng
- Genomapping Inc., Tianjin
- Genomics Group, Loma Linda, University, CA
| | - Yinghe Hu
- Shanghai Institute of Brain Functional Genomics, East China Normal University, Shanghai
| | - Kai Li
- Genomapping Inc., Tianjin
- Institute of SNP, Institute of Pharmacy and Pharmacology, National University, Hengyang
- Institute of Life Science and Biotechnology, Jinana University, Guangzhou
| |
Collapse
|
2968
|
Abstract
PURPOSE OF REVIEW In November 2003, a new, life-threatening, respiratory illness named severe acute respiratory syndrome (SARS) arose from Guangdong Province in China. The illness spread across the globe, caused many major outbreaks, and had an overall mortality rate of 11%. The purpose of this review is primarily to review the clinical features, diagnosis, and management of SARS, but also to comment briefly on the epidemiology and pathogen. RECENT FINDINGS SARS is caused by a novel coronavirus that primarily affects the lower respiratory tract. It starts with an influenza-like illness characterized by nonspecific, systemic symptoms. This is followed by the rapid development of a non-specific bronchopneumonia associated with lower tract respiratory symptoms, or gastrointestinal symptoms. Most patients recover after a week or 2, but some go on to develop acute respiratory distress syndrome. There is no proven treatment, although cocktails of broad-spectrum antibiotics, antiviral, and immunomodulatory therapy have been tried. Secondary spread can be prevented and outbreaks brought under control provided that staff wear personal protective equipment and pay close attention to good personal hygiene, and patients are isolated. The most urgent needs at present are to develop a vaccine, to develop rapid, inexpensive, accurate diagnostic tests that can give results early in the illness and within a few hours of sampling. Other needs are to investigate which therapies have the lowest adverse event/efficacy ratios. SUMMARY Up-to-date knowledge of SARS should help in early detection, isolation of high-risk patients, to reduce mortality and morbidity, and to prevent a new global epidemic arising.
Collapse
Affiliation(s)
- Timothy H Rainer
- Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
| |
Collapse
|
2969
|
Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. THE LANCET. INFECTIOUS DISEASES 2004; 4:337-48. [PMID: 15172342 PMCID: PMC7106425 DOI: 10.1016/s1473-3099(04)01044-8] [Citation(s) in RCA: 566] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Molecular diagnostics are revolutionising the clinical practice of infectious disease. Their effects will be significant in acute-care settings where timely and accurate diagnostic tools are critical for patient treatment decisions and outcomes. PCR is the most well-developed molecular technique up to now, and has a wide range of already fulfilled, and potential, clinical applications, including specific or broad-spectrum pathogen detection, evaluation of emerging novel infections, surveillance, early detection of biothreat agents, and antimicrobial resistance profiling. PCR-based methods may also be cost effective relative to traditional testing procedures. Further advancement of technology is needed to improve automation, optimise detection sensitivity and specificity, and expand the capacity to detect multiple targets simultaneously (multiplexing). This review provides an up-to-date look at the general principles, diagnostic value, and limitations of the most current PCR-based platforms as they evolve from bench to bedside.
Collapse
Affiliation(s)
- Samuel Yang
- The Johns Hopkins University, School of Medicine, Department of Emergency Medicine, Baltimore, MD, USA
| | - Richard E Rothman
- The Johns Hopkins University, School of Medicine, Department of Emergency Medicine, Baltimore, MD, USA
- Correspondence: Dr Richard E Rothman, Department of Emergency Medicine, Johns Hopkins School of Medicine, 1830 E Monument Street, Suite 6–100, Baltimore, MD 21205, USA
| |
Collapse
|
2970
|
Leung DTM, Chi Hang TF, Chun Hung M, Sheung Chan PK, Cheung JLK, Niu H, Tam JSL, Lim PL. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis 2004; 190:379-86. [PMID: 15216476 PMCID: PMC7110057 DOI: 10.1086/422040] [Citation(s) in RCA: 170] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2003] [Accepted: 02/02/2004] [Indexed: 12/18/2022] Open
Abstract
The recent outbreak of severe acute respiratory syndrome (SARS) provided an opportunity to study the antibody response of infected individuals to the causative virus, SARS coronavirus. We examined serum samples obtained from 46 patients with SARS, 40 patients with non-SARS pneumonia, and 38 healthy individuals, by use of Western blotting (WB), enzyme-linked immunoassay (ELISA), and immunofluorescence assay, using both native and bacterially produced antigens of the virus. We found a highly restricted, immunoglobulin G-dominated antibody response in patients with SARS, directed most frequently (89% by ELISA) and predominantly at the nucleocapsid. Almost all of the subjects without SARS had no antinucleocapsid antibodies. The spike protein was the next most frequently targeted, but only 63% of the patients (by ELISA) responded. Other targets of the response identified by use of WB included antigens of 80 and 60 kDa. Several nonstructural proteins cloned were not antigenic, and the culture-derived nucleocapsid appeared to be specifically degraded.
Collapse
Affiliation(s)
| | | | - Ma Chun Hung
- Clinical Immunology Unit, Shatin, New Territories, Hong Kong, HKSAR, China
| | - Paul Kay Sheung Chan
- Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, HKSAR, China
| | - Jo Lai Ken Cheung
- Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, HKSAR, China
| | - Haitao Niu
- Clinical Immunology Unit, Shatin, New Territories, Hong Kong, HKSAR, China
| | - John Siu Lun Tam
- Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, HKSAR, China
| | - Pak Leong Lim
- Clinical Immunology Unit, Shatin, New Territories, Hong Kong, HKSAR, China
- Reprints or correspondence: Prof. Pak Leong Lim, Clinical Immunology Unit, The Chinese University of Hong Kong, Prince ofWales Hospital, Shatin, New Territories, Hong Kong, HKSAR, China ()
| |
Collapse
|
2971
|
Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol 2004; 78:5619-32. [PMID: 15140959 PMCID: PMC415832 DOI: 10.1128/jvi.78.11.5619-5632.2004] [Citation(s) in RCA: 333] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV), a newly identified group 2 coronavirus, is the causative agent of severe acute respiratory syndrome, a life-threatening form of pneumonia in humans. Coronavirus replication and transcription are highly specialized processes of cytoplasmic RNA synthesis that localize to virus-induced membrane structures and were recently proposed to involve a complex enzymatic machinery that, besides RNA-dependent RNA polymerase, helicase, and protease activities, also involves a series of RNA-processing enzymes that are not found in most other RNA virus families. Here, we characterized the enzymatic activities of a recombinant form of the SARS-CoV helicase (nonstructural protein [nsp] 13), a superfamily 1 helicase with an N-terminal zinc-binding domain. We report that nsp13 has both RNA and DNA duplex-unwinding activities. SARS-CoV nsp13 unwinds its substrates in a 5'-to-3' direction and features a remarkable processivity, allowing efficient strand separation of extended regions of double-stranded RNA and DNA. Characterization of the nsp13-associated (deoxy)nucleoside triphosphatase ([dNTPase) activities revealed that all natural nucleotides and deoxynucleotides are substrates of nsp13, with ATP, dATP, and GTP being hydrolyzed slightly more efficiently than other nucleotides. Furthermore, we established an RNA 5'-triphosphatase activity for the SARS-CoV nsp13 helicase which may be involved in the formation of the 5' cap structure of viral RNAs. The data suggest that the (d)NTPase and RNA 5'-triphosphatase activities of nsp13 have a common active site. Finally, we established that, in SARS-CoV-infected Vero E6 cells, nsp13 localizes to membranes that appear to be derived from the endoplasmic reticulum and are the likely site of SARS-CoV RNA synthesis.
Collapse
Affiliation(s)
- Konstantin A Ivanov
- Institute of Virology and Immunology, University of Würzburg, Würzburg, Germany
| | | | | | | | | | | |
Collapse
|
2972
|
Abstract
Mouse hepatitis virus (MHV) replication in actively growing DBT and 17Cl-1 cells resulted in the inhibition of host cellular DNA synthesis and the accumulation of infected cells in the G(0)/G(1) phase of the cell cycle. UV-irradiated MHV failed to inhibit host cellular DNA synthesis. MHV infection in quiescent 17Cl-1 cells that had been synchronized in the G(0) phase by serum deprivation prevented infected cells from entering the S phase after serum stimulation. MHV replication inhibited hyperphosphorylation of the retinoblastoma protein (pRb), the event that is necessary for cell cycle progression through late G(1) and into the S phase. While the amounts of the cellular cyclin-dependent kinase (Cdk) inhibitors p21(Cip1), p27(Kip1), and p16(INK4a) did not change in infected cells, MHV infection in asynchronous cultures induced a clear reduction in the amounts of Cdk4 and G(1) cyclins (cyclins D1, D2, D3, and E) in both DBT and 17Cl-1 cells and a reduction in Cdk6 levels in 17Cl-1 cells. Infection also resulted in a decrease in Cdk2 activity in both cell lines. MHV infection in quiescent 17Cl-1 cells prevented normal increases in Cdk4, Cdk6, cyclin D1, and cyclin D3 levels after serum stimulation. The amounts of cyclin D2 and cyclin E were not increased significantly after serum stimulation in mock-infected cells, whereas they were decreased in MHV-infected cells, suggesting the possibility that MHV infection may induce cyclin D2 and cyclin E degradation. Our data suggested that a reduction in the amounts of G(1) cyclin-Cdk complexes in MHV-infected cells led to a reduction in Cdk activities and insufficient hyperphosphorylation of pRb, resulting in inhibition of the cell cycle in the G(0)/G(1) phase.
Collapse
Affiliation(s)
- Chun-Jen Chen
- Department of Microbiology and Immunology, The University of Texas Medical Branch at Galveston, MRB 4.146, 301 University Blvd., Galveston, TX 77555-1019, USA
| | | |
Collapse
|
2973
|
Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004; 78:5642-50. [PMID: 15140961 PMCID: PMC415834 DOI: 10.1128/jvi.78.11.5642-5650.2004] [Citation(s) in RCA: 388] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The severe acute respiratory syndrome coronavirus (SARS-CoV) synthesizes several putative viral envelope proteins, including the spike (S), membrane (M), and small envelope (E) glycoproteins. Although these proteins likely are essential for viral replication, their specific roles in SARS-CoV entry have not been defined. In this report, we show that the SARS-CoV S glycoprotein mediates viral entry through pH-dependent endocytosis. Further, we define its cellular tropism and demonstrate that virus transmission occurs through cell-mediated transfer by dendritic cells. The S glycoprotein was used successfully to pseudotype replication-defective retroviral and lentiviral vectors that readily infected Vero cells as well as primary pulmonary and renal epithelial cells from human, nonhuman primate, and, to a lesser extent, feline species. The tropism of this reporter virus was similar to that of wild-type, replication-competent SARS-CoV, and binding of purified S to susceptible target cells was demonstrated by flow cytometry. Although myeloid dendritic cells were able to interact with S and to bind virus, these cells could not be infected by SARS-CoV. However, these cells were able to transfer the virus to susceptible target cells through a synapse-like structure. Both cell-mediated infection and direct infection were inhibited by anti-S antisera, indicating that strategies directed toward this gene product are likely to confer a therapeutic benefit for antiviral drugs or the development of a SARS vaccine.
Collapse
Affiliation(s)
- Zhi-Yong Yang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Dr., Bethesda, MD 20892-3005, USA
| | | | | | | | | | | | | | | |
Collapse
|
2974
|
Abstract
The severe acute respiratory syndrome (SARS) is a highly contagious infection caused by a newly discovered strain of coronavirus (SARS-CoV). Infants born to pregnant women with SARS did not appear to acquire the infection through vertical transmission. Some newborn infants, however, developed severe intrauterine growth retardation and life-threatening gastrointestinal complications. It is now known that the clinical course and prognosis are different between paediatric and adult SARS patients. Young children (< 12 years), in general, run a less aggressive clinical course than do teenage and adult patients. Thus far, no fatalities have been reported in the paediatric age group (< or =18 years). This review describes the current understanding of the clinical manifestations, diagnostic tests, immunological profiles, patient management and outcomes of SARS-CoV infection in the paediatric population.
Collapse
Affiliation(s)
- Pak C Ng
- Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. pakcheungngcuhk.edu.hk
| | | | | | | | | |
Collapse
|
2975
|
Lee CH, Chen RF, Liu JW, Yeh WT, Chang JC, Liu PM, Eng HL, Lin MC, Yang KD. Altered p38 Mitogen-Activated Protein Kinase Expression in Different Leukocytes with Increment of Immunosuppressive Mediators in Patients with Severe Acute Respiratory Syndrome. THE JOURNAL OF IMMUNOLOGY 2004; 172:7841-7. [PMID: 15187168 DOI: 10.4049/jimmunol.172.12.7841] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Severe acute respiratory syndrome (SARS) has spread to a global pandemic, especially in Asia. The transmission route of SARS has been clarified, but the immunopathogenesis of SARS is unclear. In an age-matched case-control design, we studied immune parameters in 15 SARS patients who were previously healthy. Plasma was harvested for detection of virus load, cytokines, and nitrite/nitrate levels, and blood leukocytes were subjected to flow cytometric analysis of intracellular mitogen-activated protein kinases (MAPKs) in different leukocytes. Patients with SARS had significantly higher IL-8 levels (p = 0.016) in early stage, and higher IL-2 levels (p = 0.039) in late stage than normal controls. Blood TNF-alpha, IL-6, and IL-10, and nitrite/nitrate levels were not significantly elevated. In contrast, TGF-beta and PGE(2) levels were significantly elevated in SARS patients. Five of the 15 SARS patients had detectable coronaviruses in blood, but patients with detectable and undetectable viremia had no different profiles of immune mediators. Flow cytometric analysis of MAPKs activation by phospho-p38 and phospho-p44/42 (extracellular signal-regulated kinase) expression showed that augmented p38 activation (p = 0.044) of CD14 monocytes associated with suppressed p38 activation (p = 0.033) of CD8 lymphocytes was found in SARS patients. These results suggest that regulation of TGF-beta and PGE(2) production and MAPKs activation in different leukocytes may be considered while developing therapeutics for the SARS treatment.
Collapse
Affiliation(s)
- Chen-Hsiang Lee
- Department of Internal Medicine, Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niau-Sung, Kaohsiung 833, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
2976
|
Ingallinella P, Bianchi E, Finotto M, Cantoni G, Eckert DM, Supekar VM, Bruckmann C, Carfi A, Pessi A. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A 2004; 101:8709-14. [PMID: 15161975 PMCID: PMC423260 DOI: 10.1073/pnas.0402753101] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2003] [Indexed: 11/18/2022] Open
Abstract
The causative agent of a recent outbreak of an atypical pneumonia, known as severe acute respiratory syndrome (SARS), has been identified as a coronavirus (CoV) not belonging to any of the previously identified groups. Fusion of coronaviruses with the host cell is mediated by the envelope spike protein. Two regions within the spike protein of SARS-CoV have been identified, showing a high degree of sequence conservation with the other CoV, which are characterized by the presence of heptad repeats (HR1 and HR2). By using synthetic and recombinant peptides corresponding to the HR1 and HR2 regions, we were able to characterize the fusion-active complex formed by this novel CoV by CD, native PAGE, proteolysis protection analysis, and size-exclusion chromatography. HR1 and HR2 of SARS-CoV associate into an antiparallel six-helix bundle, with structural features typical of the other known class I fusion proteins. We have also mapped the specific boundaries of the region, within the longer HR1 domain, making contact with the shorter HR2 domain. Notably, the inner HR1 coiled coil is a stable alpha-helical domain even in the absence of interaction with the HR2 region. Inhibitors binding to HR regions of fusion proteins have been shown to be efficacious against many viruses, notably HIV. Our results may help in the design of anti-SARS therapeutics.
Collapse
Affiliation(s)
- Paolo Ingallinella
- Istituto di Ricerche di Biologia Molecolare P. Angeletti, Via Pontina Km 30.600, 00040 Pomezia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
2977
|
Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, Lit LCW, Hui DSC, Chan MHM, Chung SSC, Sung JJY. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103. [PMID: 15030519 PMCID: PMC1808997 DOI: 10.1111/j.1365-2249.2004.02415.x] [Citation(s) in RCA: 929] [Impact Index Per Article: 46.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel coronavirus, but its immunopathological mechanisms have not yet been fully elucidated. We investigated changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS. Cytokine profile of SARS patients showed marked elevation of Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4. The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10). Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all P < 0.001). Together, the elevation of Th1 cytokine IFN-gamma, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyperinnate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils.
Collapse
Affiliation(s)
- C K Wong
- Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2978
|
Yao YX, Ren J, Heinen P, Zambon M, Jones IM. Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis 2004; 190:91-8. [PMID: 15195247 PMCID: PMC7110131 DOI: 10.1086/421280] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2003] [Accepted: 12/11/2003] [Indexed: 01/13/2023] Open
Abstract
Severe acute respiratory syndrome (SARS) coronavirus (SCoV) spike (S) protein is the major surface antigen of the virus and is responsible for receptor binding and the generation of neutralizing antibody. To investigate SCoV S protein, full-length and individual domains of S protein were expressed on the surface of insect cells and were characterized for cleavability and reactivity with serum samples obtained from patients during the convalescent phase of SARS. S protein could be cleaved by exogenous trypsin but not by coexpressed furin, suggesting that the protein is not normally processed during infection. Reactivity was evident by both flow cytometry and Western blot assays, but the pattern of reactivity varied according to assay and sequence of the antigen. The antibody response to SCoV S protein involves antibodies to both linear and conformational epitopes, with linear epitopes associated with the carboxyl domain and conformational epitopes associated with the amino terminal domain. Recombinant SCoV S protein appears to be a suitable antigen for the development of an efficient and sensitive diagnostic test for SARS, but our data suggest that assay format and choice of S antigen are important considerations.
Collapse
Affiliation(s)
- Yong Xiu Yao
- School of Animal and Microbial Sciences, University of Reading, Reading,London, United Kingdom
| | - Junyuan Ren
- School of Animal and Microbial Sciences, University of Reading, Reading,London, United Kingdom
| | - Paul Heinen
- Public Health Laboratory Service, Enteric and Respiratory Virus Laboratory, London, United Kingdom
| | - Maria Zambon
- Public Health Laboratory Service, Enteric and Respiratory Virus Laboratory, London, United Kingdom
| | - Ian M. Jones
- School of Animal and Microbial Sciences, University of Reading, Reading,London, United Kingdom
- Reprints or correspondence: Dr. Ian M. Jones, School of Animal and Microbial Sciences, University of Reading, Reading RG6 6AJ, UK()
| |
Collapse
|
2979
|
Haas W, Krause G, Marcus U, Stark K, Ammon A, Burger R. ["Emerging infectious diseases". Dengue-fever, West-Nile-fever, SARS, avian influenza, HIV]. Internist (Berl) 2004; 45:684-92. [PMID: 15107983 PMCID: PMC7079988 DOI: 10.1007/s00108-004-1199-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Some emerging infectious diseases have recently become endemic in Germany. Others remain confined to specific regions in the world. Physicians notice them only when travelers after infection in endemic areas present themselves with symptoms. Several of these emerging infections will be explained. HIV is an example for an imported pathogen which has become endemic in Germany. SARS and avian influenza are zoonoses with the potential to spread from person to person. Avian influenza in humans provides a possibility for the reassortment of a potential new pandemic strain. Outbreaks of dengue fever in endemic areas are reflected in increased infections in travelers returning from these areas. Currently, West-Nile-virus infections are only imported into Germany. The timely implementation of diagnostic, therapeutic and infection control measures requires physicians to include these diseases in their differential diagnosis. To achieve this goal, good cooperation between physicians, laboratories and the public health service is essential.
Collapse
Affiliation(s)
- W. Haas
- Robert Koch-Institut, Berlin
| | | | | | | | - A. Ammon
- Robert Koch-Institut, Berlin
- Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Seestraße 10, 13353 Berlin
| | | |
Collapse
|
2980
|
Abstract
Approximately 20% of patients with severe acute respiratory syndrome (SARS) develop respiratory failure that requires admission to an intensive care unit (ICU). Old age, comorbidity, and elevated lactate dehydrogenase on hospital admission are associated with increased risk for ICU admission. ICU admission usually is late and occurs 8 to 10 days after symptom onset. Acute respiratory distress syndrome occurs in almost all admitted patients and most require mechanical ventilation. ICU admission is associated with significant morbidity, particularly an apparent increase in the incidence of barotrauma and nosocomial sepsis. Long-term mortality for patients admitted to the ICU ranges from 30% to 50%. Many procedures in ICUs pose a high risk for transmission of SARS coronavirus to health care workers. Contact and airborne infection isolation precautions, in addition to standard precautions, should be applied when caring for patients with SARS. Ensuring staff safety is important to maintain staff morale and delivery of adequate services.
Collapse
Affiliation(s)
- Gavin M. Joynt
- Department of Anesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China.
| | | |
Collapse
|
2981
|
Lai KN, Tsang KW, Seto WH, Ooi CGC. Clinical, Laboratory, and Radiologic Manifestation of SARS. Curr Infect Dis Rep 2004; 6:213-219. [PMID: 15142485 PMCID: PMC7088556 DOI: 10.1007/s11908-004-0011-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Severe acute respiratory syndrome (SARS) is a highly contagious and predominantly pneumonic illness caused by a novel coronavirus now commonly known as SARS-CoV. This article describes the key diagnostic clinical features, radiologic features, and investigation profiles of affected patients. We summarize our understanding from anecdotal experience and limited published data on the use of antiviral and corticosteroid therapy in the management of this highly contagious disease.
Collapse
Affiliation(s)
- Kar Neng Lai
- University Department of Medicine, The University of Hong Kong, Room 409, Professorial Block, Queen Mary Hospital, Pokfulam, Hong Kong.
| | | | | | | |
Collapse
|
2982
|
Cui HJ, Tong XL, Li P, Hao YX, Chen XG, Li AG, Zhang ZY, Duan J, Zhen M, Zhang B, Hua CJ, Gong YW. Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: retrospective analysis. World J Gastroenterol 2004; 10:1652-5. [PMID: 15162543 PMCID: PMC4572772 DOI: 10.3748/wjg.v10.i11.1652] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2003] [Revised: 10/04/2003] [Accepted: 10/22/2003] [Indexed: 12/15/2022] Open
Abstract
AIM To evaluate the hepatic function in patients with severe acute respiratory syndrome (SARS) and possible causes of hepatic disorder in these patients. METHODS One hundred and eighty-two patients with SARS were employed in a retrospective study that investigated hepatic dysfunction. Liver alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH) were analyzed in these patients. Patients with different hospital treatments were further investigated. RESULTS Of the 182 patients, 128(70.3%) had abnormal ALT activity, 57(31.3%) had abnormal AST activity and 87(47.8%) had abnormal LDH activity. The peak of elevated hepatic enzyme activities occurred between the sixth day and the tenth day after the first day of reported fever. Of the 182 patients, 160(87.9%) had been treated with antibiotics, 137(75.2%) with Ribavirin, and 115(63.2%) with methylpredisolone. There was no statistically significant correlation between the duration of Ribavirin treatment and hepatic dysfunction. CONCLUSION Abnormal liver functions were common in patients with SARS and could be associated with virus replication in the liver.
Collapse
Affiliation(s)
- Hui-Juan Cui
- Chinese-Japanese Friendship Hospital, Beijing 100029, China.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2983
|
Poon LLM, Chan KH, Nicholls JM, Zheng BJ, Yuen KY, Guan Y, Peiris JSM. Characterization of a novel coronavirus responsible for severe acute respiratory syndrome. ACTA ACUST UNITED AC 2004; 1263:805-808. [PMID: 32288144 PMCID: PMC7135436 DOI: 10.1016/j.ics.2004.02.105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In February, a new avian H5N1/03 virus took two persons' lives in Hong Kong. After this incidence, a newly emerged disease has been identified, associated with pneumonia in infected patients. Here we report that a newly discovered coronoavirus (Cov) is responsible for this disease. In addition, the basic features, diagnosis and possible animal sources of Severe Acute Respiratory Syndrome (SARS) Cov are also discussed.
Collapse
Affiliation(s)
- L L M Poon
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| | - K H Chan
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| | - J M Nicholls
- Department of Pathology, The University of Hong Kong, Hong Kong SAR, PR China
| | - B J Zheng
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| | - K Y Yuen
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| | - Y Guan
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| | - J S M Peiris
- Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China
| |
Collapse
|
2984
|
Poon LLM, Leung CSW, Tashiro M, Chan KH, Wong BWY, Yuen KY, Guan Y, Peiris JSM. Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. Clin Chem 2004; 50:1050-2. [PMID: 15054079 PMCID: PMC7108160 DOI: 10.1373/clinchem.2004.032011] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Leo L M Poon
- Department of Microbiology, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR.
| | | | | | | | | | | | | | | |
Collapse
|
2985
|
Babcock GJ, Esshaki DJ, Thomas WD, Ambrosino DM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004; 78:4552-60. [PMID: 15078936 PMCID: PMC387703 DOI: 10.1128/jvi.78.9.4552-4560.2004] [Citation(s) in RCA: 183] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), has recently been identified as the causative agent of severe acute respiratory syndrome (SARS). SARS-CoV appears similar to other coronaviruses in both virion structure and genome organization. It is known for other coronaviruses that the spike (S) glycoprotein is required for both viral attachment to permissive cells and for fusion of the viral envelope with the host cell membrane. Here we describe the construction and expression of a soluble codon-optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glycoprotein (S(1190)). The codon-optimized and native S glycoproteins exhibit similar molecular weight as determined by Western blot analysis, indicating that synthetic S glycoprotein is modified correctly in a mammalian expression system. S(1190) binds to the surface of Vero E6 cells, a cell permissive to infection, as demonstrated by fluorescence-activated cell sorter analysis, suggesting that S(1190) maintains the biologic activity present in native S glycoprotein. This interaction is blocked with serum obtained from recovering SARS patients, indicating that the binding is specific. In an effort to map the ligand-binding domain of the SARS-CoV S glycoprotein, carboxy- and amino-terminal truncations of the S(1190) glycoprotein were constructed. Amino acids 270 to 510 were the minimal receptor-binding region of the SARS-CoV S glycoprotein as determined by flow cytometry. We speculate that amino acids 1 to 510 of the SARS-CoV S glycoprotein represent a unique domain containing the receptor-binding site (amino acids 270 to 510), analogous to the S1 subunit of other coronavirus S glycoproteins.
Collapse
Affiliation(s)
- Gregory J Babcock
- Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, Massachusetts 02130, USA.
| | | | | | | |
Collapse
|
2986
|
Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DAK, Wu TC. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004; 78:4638-45. [PMID: 15078946 PMCID: PMC387705 DOI: 10.1128/jvi.78.9.4638-4645.2004] [Citation(s) in RCA: 145] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Severe acute respiratory syndrome (SARS) is a serious threat to public health and the economy on a global scale. The SARS coronavirus (SARS-CoV) has been identified as the etiological agent for SARS. Thus, vaccination against SARS-CoV may represent an effective approach to controlling SARS. DNA vaccines are an attractive approach for SARS vaccine development, as they offer many advantages over conventional vaccines, including stability, simplicity, and safety. Our investigators have previously shown that DNA vaccination with antigen linked to calreticulin (CRT) dramatically enhances major histocompatibility complex class I presentation of linked antigen to CD8(+) T cells. In this study, we have employed this CRT-based enhancement strategy to create effective DNA vaccines using SARS-CoV nucleocapsid (N) protein as a target antigen. Vaccination with naked CRT/N DNA generated the most potent N-specific humoral and T-cell-mediated immune responses in vaccinated C57BL/6 mice among all of the DNA constructs tested. Furthermore, mice vaccinated with CRT/N DNA were capable of significantly reducing the titer of challenging vaccinia virus expressing the N protein of the SARS virus. These results show that a DNA vaccine encoding CRT linked to a SARS-CoV antigen is capable of generating strong N-specific humoral and cellular immunity and may potentially be useful for control of infection with SARS-CoV.
Collapse
Affiliation(s)
- Tae Woo Kim
- Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2987
|
Olszewska W, Helson R, Openshaw PJM. Vaccines for the prevention of respiratory viral infections: problems and current status. Expert Opin Investig Drugs 2004; 13:681-9. [PMID: 15174954 DOI: 10.1517/13543784.13.6.681] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Acute respiratory virus infections cause the majority of lower respiratory tract illnesses and hospitalisations of infants and the elderly. The emergence of new respiratory viruses and a high probability that influenza will cause further pandemics highlights the necessity for developing better preventative strategies. Although there is a clear and pressing need for vaccines to prevent respiratory syncytial virus, rhinoviruses, coronaviruses, parainfluenza and human metapneumovirus, progress has been extremely slow. This review presents the current status of vaccine development for respiratory viral diseases and outlines novel approaches for the future.
Collapse
Affiliation(s)
- Wieslawa Olszewska
- Department of Respiratory Medicine, Wright Fleming Institute for Infection and Immunity, National Heart and Lung Division, Faculty of Medicine, Imperial College, St. Mary's Campus, Paddington, London W2 1PG, UK.
| | | | | |
Collapse
|
2988
|
Chen W, Xu Z, Mu J, Yang L, Gan H, Mu F, Fan B, He B, Huang S, You B, Yang Y, Tang X, Qiu L, Qiu Y, Wen J, Fang J, Wang J. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Microbiol 2004; 53:435-438. [PMID: 15096554 DOI: 10.1099/jmm.0.45561-0] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
To understand the time-course of viraemia and antibody responses to severe acute respiratory syndrome-associated coronavirus (SARS-CoV), RT-PCR and ELISA were used to assay 376 blood samples from 135 SARS patients at various stages of the illness, including samples from patients who were in their early convalescent phase. The results showed that IgM antibodies decreased and became undetectable 11 weeks into the recovery phase. IgG antibodies, however, remained detectable for a period beyond 11 weeks and were found in 100 % of patients in the early convalescent phase. SARS-CoV viraemia mainly appeared 1 week after the onset of illness and then decreased over a period of 1 month, becoming undetectable in the blood samples of the convalescent patients. At the peak of viraemia, viral RNA was detectable in 75 % of blood samples from patients who were clinically diagnosed with SARS 1 or 2 weeks before the test.
Collapse
Affiliation(s)
- Weijun Chen
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Zuyuan Xu
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Jingsong Mu
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Ling Yang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Haixue Gan
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Feng Mu
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Baoxing Fan
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Bo He
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Shengyong Huang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Bo You
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Yongkui Yang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Xiangjun Tang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Ling Qiu
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Yan Qiu
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Jie Wen
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Jianqiu Fang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| | - Jian Wang
- Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China
| |
Collapse
|
2989
|
Differential virological diagnosis of acute respiratory infections in suspect SARS patients. INTERNATIONAL CONGRESS SERIES 2004; 1263:395-397. [PMID: 32288141 PMCID: PMC7125625 DOI: 10.1016/j.ics.2004.02.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The NIC in Lyon has been involved in the virological diagnosis of suspect severe acute respiratory syndrome (SARS) patients. In March, the French medical authorities organized a medical surveillance of the medical staff who had returned from the French hospital in Hanoi. Each person presenting or not with respiratory symptoms was sampled systematically by the nearest general practitioner (GP) belonging to the influenza network surveillance in the community called GROG and the samples were sent to the NICs located either in Paris or in Lyon. We also received samples from patients hospitalized in the south of France suffering from acute respiratory infection soon after a journey in Asia. We implemented a PCR diagnosis for the human respiratory viruses: influenza A and B, Parainfluenza (Type 1 to Type 4), Metapneumovirus, RSV, Rhinovirus, Enterovirus, Adenovirus. In April, we set up the PCR detection of the SARS-associated coronavirus Urbani strain. The practitioners performed respiratory samples. From 14 March to 15 May we received and tested 88 respiratory samples, respectively, 19 were realized by GPs from the community network and 69 came from hospitalized patients. We never detected the urbani coronavirus strain. However, we detected respiratory viruses in 24% of the cases: the most frequent virus was influenza A H3N2 (11%) and Parainfluenza type 3 (8%). RSV, influenza A H1N1 and Rhinovirus were also detected 2, 1 and 1 cases, respectively. All the positive samples except the rhinovirus came from hospitalized patients. The patients were sampled once and all of them recovered rapidly.
Collapse
|
2990
|
Abstract
PURPOSE OF REVIEW Severe acute respiratory syndrome (SARS) is an infectious disease first recognized in November 2002 in Guangdong Province, China. It spread to many countries all over the world during February to June 2003, with 8098 cases reported. Twenty-one percent of the affected people were health care workers. Because SARS is a new emerging disease, this review describes the current understanding about the etiology, clinical pictures, laboratory and radiological findings of SARS. RECENT FINDINGS Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) was quickly found to be the etiological agent of SARS in April 2003. The transmission of SARS-CoV between human beings is mainly due to close contact. Using barrier precautions, the transmission of SARS-CoV can be prevented. The most common clinical presentations of patients with SARS include fever, cough, and dyspnea. The common laboratory findings include lymphopenia, thrombocytopenia, elevated serum alanine and aspartate aminotransferase, lactate dehydrogenase, creatine phosphokinase, and C-reactive protein. The most common radiological finding is pneumonic lesion(s) in the chest radiogram. Many patients experience exacerbation of clinical symptoms in the second week of disease course and some may progress to respiratory failure and need mechanical ventilatory support. The overall case fatality rate is 9.6%. The current method of treatment of SARS is still controversial. SUMMARY SARS is an infectious disease with high contagiousness and a high mortality rate. Early case identification and infection control are two important factors to limit its spread.
Collapse
Affiliation(s)
- Jann-Tay Wang
- Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | | |
Collapse
|
2991
|
Turner BC, Hemmila EM, Beauchemin N, Holmes KV. Receptor-dependent coronavirus infection of dendritic cells. J Virol 2004; 78:5486-90. [PMID: 15113927 PMCID: PMC400329 DOI: 10.1128/jvi.78.10.5486-5490.2004] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In several mammalian species, including humans, coronavirus infection can modulate the host immune response. We show a potential role of dendritic cells (DC) in murine coronavirus-induced immune modulation and pathogenesis by demonstrating that the JAW SII DC line and primary DC from BALB/c mice and p/p mice with reduced expression of the murine coronavirus receptor, murine CEACAM1a, are susceptible to murine coronavirus infection by a receptor-dependent pathway.
Collapse
Affiliation(s)
- Brian C Turner
- Department of Microbiology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
| | | | | | | |
Collapse
|
2992
|
Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, Bordignon C, Poli G, Clementi M. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis 2004; 10:413-8. [PMID: 15109406 PMCID: PMC3322807 DOI: 10.3201/eid1003.030683] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
During the recent severe acute respiratory (SARS) outbreak, the etiologic agent was identified as a new coronavirus (CoV). We have isolated a SARS-associated CoV (SARS-CoV) strain by injecting Vero cells with a sputum specimen from an Italian patient affected by a severe pneumonia; the patient traveled from Vietnam to Italy in March 2003. Ultrastructural analysis of infected Vero cells showed the virions within cell vesicles and around the cell membrane. The full-length viral genome sequence was similar to those derived from the Hong-Kong Hotel M isolate. By using both real-time reverse transcription–polymerase chain reaction TaqMan assay and an infectivity plaque assay, we determined that approximately 360 viral genomes were required to generate a PFU. In addition, heparin (100 μg/mL) inhibited infection of Vero cells by 50%. Overall, the molecular and biologic characteristics of the strain HSR1 provide evidence that SARS-CoV forms a fourth genetic coronavirus group with distinct genomic and biologic features.
Collapse
Affiliation(s)
- Elisa Vicenzi
- P2-P3 Laboratories, DIBIT, San Raffaele Scientific Institute, Via Olgettina n. 58, 20132 Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
2993
|
Hsueh PR, Chen PJ, Hsiao CH, Yeh SH, Cheng WC, Wang JL, Chiang BL, Chang SC, Chang FY, Wong WW, Kao CL, Yang PC. Patient data, early SARS epidemic, Taiwan. Emerg Infect Dis 2004; 10:489-93. [PMID: 15109419 DOI: 10.3201/eid1003.030571] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Of the first 10 patients in the epidemic of severe acute respiratory syndrome (SARS) in Taiwan, 4 were closely associated with a SARS patient in an airplane. Loose stools or diarrhea, hemophagocytosis syndrome, and high serum levels of interleukin (IL)-6, IL-8, and tumor necrosis factor-a associated with lung lesions were found in all 10 patients.
Collapse
Affiliation(s)
- Po-Ren Hsueh
- National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2994
|
Muller MP, McGeer A, Straus SE, Hawryluck L, Gold WL. Clinical trials and novel pathogens: lessons learned from SARS. Emerg Infect Dis 2004; 10:389-94. [PMID: 15109402 PMCID: PMC3322802 DOI: 10.3201/eid1003.030702] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
During the recent global outbreak of severe acute respiratory syndrome (SARS), thousands of patients received treatments of uncertain efficacy and known toxicity such as ribavirin and corticosteroids. Despite this, no controlled clinical trials assessing the efficacy of these agents were conducted. If a second global SARS outbreak occurred, clinicians would not have controlled data on which to base therapeutic decisions. We discuss the unique methodologic and logistical challenges faced by researchers who attempt to conduct controlled trials of therapeutic agents during an outbreak of a novel or unknown infectious pathogen. We draw upon our own experience in attempting to conduct a randomized controlled trial (trial) of ribavirin therapy for SARS and discuss the lessons learned. Strategies to facilitate future clinical trials during outbreaks of unknown or novel pathogens are also presented.
Collapse
Affiliation(s)
- Matthew P. Muller
- Mount Sinai Hospital, Toronto, Ontario, Canada
- University of Toronto, Toronto, Canada
| | - Allison McGeer
- Mount Sinai Hospital, Toronto, Ontario, Canada
- University of Toronto, Toronto, Canada
| | - Sharon E. Straus
- University Health Network, Toronto, Ontario, Canada
- University of Toronto, Toronto, Canada
| | - Laura Hawryluck
- University Health Network, Toronto, Ontario, Canada
- University of Toronto, Toronto, Canada
| | - Wayne L. Gold
- University Health Network, Toronto, Ontario, Canada
- University of Toronto, Toronto, Canada
| |
Collapse
|
2995
|
Sung JJY, Wu A, Joynt GM, Yuen KY, Lee N, Chan PKS, Cockram CS, Ahuja AT, Yu LM, Wong VW, Hui DSC. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59:414-20. [PMID: 15115870 PMCID: PMC1746995 DOI: 10.1136/thx.2003.014076] [Citation(s) in RCA: 136] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. METHOD One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for > or =4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders. RESULTS Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset. CONCLUSION The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomised controlled trials are needed to ascertain its efficacy in this condition.
Collapse
Affiliation(s)
- J J Y Sung
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2996
|
|
2997
|
Davidson A, Siddell S. Potential for antiviral treatment of severe acute respiratory syndrome. Curr Opin Infect Dis 2004; 16:565-71. [PMID: 14624107 DOI: 10.1097/00001432-200312000-00009] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW Severe acute respiratory syndrome is a new, sometimes lethal disease of humans that is caused by a novel coronavirus. To date there have been over 750 related deaths and there is clearly an urgent need to develop specific antiviral drugs to combat this disease. In this review, the authors shall focus on the molecular biology of the coronavirus and suggest how this information can be used to identify possible targets for antiviral drugs. RECENT FINDINGS Within a remarkably short period of time, the severe acute respiratory syndrome coronavirus has been isolated, its genome has been sequenced and the structure of at least one key viral enzyme has been deduced. In addition, bioinformatic analysis has predicted a number of enzymatic activities associated with proteins of the viral replicase-transcriptase complex. In some cases, these functions have been confirmed by biochemical analysis. Thus, there has been significant progress in the rational approach to anti-severe acute respiratory syndrome coronavirus drug design. This approach, combined with the random screening of licensed compounds or existing compound libraries, should result in the identification of novel lead compounds and the expeditious development of antiviral drugs. SUMMARY Although the initial severe acute respiratory syndrome epidemic has been controlled by conventional measures, the animal reservoir for the coronavirus progenitor has not been identified. It is therefore likely that the virus will be reintroduced into the human population in the future. When this happens, the most economical and effective way to contain the virus will be the therapeutic use of antiviral drugs.
Collapse
Affiliation(s)
- Andrew Davidson
- Department of Pathology and Microbiology, Medical and Veterinary Sciences, University of Bristol, Bristol, UK
| | | |
Collapse
|
2998
|
Affiliation(s)
- Lindsay Nicolle
- Department of Internal Medicine and Medical Microbiology, University of Manitoba, Health Sciences Centre, GG443 - 820 Sherbrook, R3A 1R9 Winnipeg, Manitoba Canada
| |
Collapse
|
2999
|
Affiliation(s)
- Kang Sim
- Department of Adult Psychiatry III, Institute of Mental Health/Woodbridge Hospital, 10 Buangkok View, Singapore 539747.
| | | |
Collapse
|
3000
|
Liang W, Zhu Z, Guo J, Liu Z, He X, Zhou W, Chin DP, Schuchat A. Severe acute respiratory syndrome, Beijing, 2003. Emerg Infect Dis 2004; 10:25-31. [PMID: 15078593 PMCID: PMC3092360 DOI: 10.3201/eid1001.030553] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The largest outbreak of severe acute respiratory syndrome (SARS) struck Beijing in spring 2003. Multiple importations of SARS to Beijing initiated transmission in several healthcare facilities. Beijing’s outbreak began March 5; by late April, daily hospital admissions for SARS exceeded 100 for several days; 2,521 cases of probable SARS occurred. Attack rates were highest in those 20–39 years of age; 1% of cases occurred in children <10 years. The case-fatality rate was highest among patients >65 years (27.7% vs. 4.8% for those 20–64 years, p < 0.001). Healthcare workers accounted for 16% of probable cases. The proportion of case-patients without known contact to a SARS patient increased significantly in May. Implementation of early detection, isolation, contact tracing, quarantine, triage of case-patients to designated SARS hospitals, and community mobilization ended the outbreak.
Collapse
Affiliation(s)
- Wannian Liang
- Beijing Municipal Health Bureau and Beijing Municipal Centers for Disease Prevention and Control, Beijing, China
| | - Zonghan Zhu
- Beijing Municipal Health Bureau and Beijing Municipal Centers for Disease Prevention and Control, Beijing, China
| | - Jiyong Guo
- Beijing Municipal Health Bureau and Beijing Municipal Centers for Disease Prevention and Control, Beijing, China
| | - Zejun Liu
- Beijing Municipal Health Bureau and Beijing Municipal Centers for Disease Prevention and Control, Beijing, China
| | - Xiong He
- Beijing Municipal Health Bureau and Beijing Municipal Centers for Disease Prevention and Control, Beijing, China
| | - Weigong Zhou
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Anne Schuchat
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | |
Collapse
|